Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.
Los Angeles Times (LT) - FRIDAY July 23, 1993 Edition: Home Edition Section: Business Page: 1 Pt. D Col. 5 Word Count: 383
Marlene Cimons; Times Staff Writer
The decision upholds Burroughs' exclusive patent on AZT, the most widely prescribed AIDS treatment. But it is expected to be reviewed by an appeals court.
The decision was hailed as a "clear victory" by Burroughs, while a spokesman for Barr Laboratories, one of two companies seeking to make generic AZT, warned: "It's not over, not by a long stretch."
The decision was good news for investors in Wellcome, Burroughs Wellcome's British parent. Its shares rose 37 1/2 cents to close at $9.50 on the New York Stock Exchange. Barr Labs' stock fell $1.625, to $16.125, on the American Stock Exchange.
AZT typically costs AIDS patients about $2,200 a year. The competing firms have pledged that their product would cost 50% less.
The legal battle centers around the contributions of researchers at the federal government's National Cancer Institute, who worked with Burroughs scientists in the mid-1980s on studies of the drug.
Barr Laboratories of Pomona, N.Y., and Novopharm Ltd. of Scarborough, Canada, claim that the work of NCI's Dr. Samuel Broder, now institute director, and Dr. Hiroaki Mitsuya helped determine the value of AZT as an AIDS therapy.
The National Institutes of Health, of which NCI is a part, even granted Barr a license to make the drug--an action that spurred a Burroughs lawsuit, which resulted in Thursday's decision.
U.S. District Judge Malcolm Howard said, "the court has felt for some time that U.S. law . . . dictates that Burroughs Wellcome scientists were, in fact, the sole inventors of AZT."
Paul A. Holcombe Jr., Burroughs' vice president and general counsel, said company officials "believe strongly that this decision is in the best interests of the HIV community and all persons for whom life-saving medications have not yet been found," because it supports a patent system designed to encourage drug innovation by pharmaceutical companies.
But Barr spokesman Harold Cohen said Barr would continue its fight, adding: "The unfortunate part of all of this is that it will delay generic AZT from getting into the marketplace."
The Burroughs patent does not expire until 2005.
930723
LT930708
Copyright © 1993 - Los Angeles Times. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Los Angeles Times, Permissions, Times Mirror Square, Los Angeles, CA 90053. http://www.latimes.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .